Logo image of ALT

ALTIMMUNE INC (ALT) Stock Fundamental Analysis

NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD

5.665  +0.08 (+1.34%)

Fundamental Rating

3

ALT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ALT as it has an excellent financial health rating, but there are worries on the profitability. ALT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALT has reported negative net income.
In the past year ALT has reported a negative cash flow from operations.
In the past 5 years ALT always reported negative net income.
In the past 5 years ALT always reported negative operating cash flow.
ALT Yearly Net Income VS EBIT VS OCF VS FCFALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ALT has a worse Return On Assets (-68.24%) than 64.88% of its industry peers.
Looking at the Return On Equity, with a value of -76.97%, ALT is in line with its industry, outperforming 52.05% of the companies in the same industry.
Industry RankSector Rank
ROA -68.24%
ROE -76.97%
ROIC N/A
ROA(3y)-50.39%
ROA(5y)-43.11%
ROE(3y)-56.08%
ROE(5y)-47.74%
ROIC(3y)N/A
ROIC(5y)N/A
ALT Yearly ROA, ROE, ROICALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALT Yearly Profit, Operating, Gross MarginsALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K

More info and screens

8

2. Health

2.1 Basic Checks

ALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALT has more shares outstanding
Compared to 5 years ago, ALT has more shares outstanding
ALT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALT Yearly Shares OutstandingALT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALT Yearly Total Debt VS Total AssetsALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ALT has an Altman-Z score of 9.36. This indicates that ALT is financially healthy and has little risk of bankruptcy at the moment.
ALT has a Altman-Z score of 9.36. This is amongst the best in the industry. ALT outperforms 86.45% of its industry peers.
There is no outstanding debt for ALT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.36
ROIC/WACCN/A
WACC10.1%
ALT Yearly LT Debt VS Equity VS FCFALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 13.11 indicates that ALT has no problem at all paying its short term obligations.
ALT has a better Current ratio (13.11) than 85.56% of its industry peers.
ALT has a Quick Ratio of 13.11. This indicates that ALT is financially healthy and has no problem in meeting its short term obligations.
ALT has a better Quick ratio (13.11) than 85.56% of its industry peers.
Industry RankSector Rank
Current Ratio 13.11
Quick Ratio 13.11
ALT Yearly Current Assets VS Current LiabilitesALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.70% over the past year.
The Revenue for ALT has decreased by -95.31% in the past year. This is quite bad
The Revenue for ALT have been decreasing by -67.82% on average. This is quite bad
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-95.31%
Revenue growth 3Y-83.45%
Revenue growth 5Y-67.82%
Sales Q2Q%0%

3.2 Future

The Earnings Per Share is expected to grow by 28.08% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALT will show a very strong growth in Revenue. The Revenue will grow by 869.81% on average per year.
EPS Next Y2.14%
EPS Next 2Y-10.62%
EPS Next 3Y-0.73%
EPS Next 5Y28.08%
Revenue Next Year16566.6%
Revenue Next 2Y8065.01%
Revenue Next 3Y1885.41%
Revenue Next 5Y869.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALT Yearly Revenue VS EstimatesALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 500M 1B
ALT Yearly EPS VS EstimatesALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALT Price Earnings VS Forward Price EarningsALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALT Per share dataALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.62%
EPS Next 3Y-0.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTIMMUNE INC

NASDAQ:ALT (5/22/2025, 10:18:05 AM)

5.665

+0.08 (+1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners58.24%
Inst Owner Change-6.19%
Ins Owners0.93%
Ins Owner Change1.61%
Market Cap436.26M
Analysts81.67
Price Target22.29 (293.47%)
Short Float %29.55%
Short Ratio8.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.33%
Min EPS beat(2)0.21%
Max EPS beat(2)10.46%
EPS beat(4)3
Avg EPS beat(4)4.34%
Min EPS beat(4)-1.62%
Max EPS beat(4)10.46%
EPS beat(8)7
Avg EPS beat(8)12.53%
EPS beat(12)11
Avg EPS beat(12)13.27%
EPS beat(16)13
Avg EPS beat(16)4.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.66%
EPS NQ rev (1m)-1.72%
EPS NQ rev (3m)3.93%
EPS NY rev (1m)11.28%
EPS NY rev (3m)11.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21813.08
P/FCF N/A
P/OCF N/A
P/B 3.53
P/tB 3.53
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0
BVpS1.6
TBVpS1.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.24%
ROE -76.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.39%
ROA(5y)-43.11%
ROE(3y)-56.08%
ROE(5y)-47.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.11
Quick Ratio 13.11
Altman-Z 9.36
F-Score2
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y2.14%
EPS Next 2Y-10.62%
EPS Next 3Y-0.73%
EPS Next 5Y28.08%
Revenue 1Y (TTM)-95.31%
Revenue growth 3Y-83.45%
Revenue growth 5Y-67.82%
Sales Q2Q%0%
Revenue Next Year16566.6%
Revenue Next 2Y8065.01%
Revenue Next 3Y1885.41%
Revenue Next 5Y869.81%
EBIT growth 1Y-23.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.36%
EBIT Next 3Y-16.51%
EBIT Next 5Y11.56%
FCF growth 1Y-5.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.33%
OCF growth 3YN/A
OCF growth 5YN/A